NicOx S.A. (Eurolist: COX) today reported financial results for the quarter ended March 31, 2007 and provided an update on its collaboration with Axcan Pharma Inc. in chronic liver diseases (see separate press release). The Company significantly strengthened its financial position during the quarter with a capital increase which raised total net proceeds of EUR 120.7 million and was completed on February 16, 2007. On March 31, 2007, NicOx had cash, cash equivalents and current financial instruments of EUR 201.2 million, compared to EUR 81.7 million on December 31, 2006.
